Saquinavir

Identification

Name

Saquinavir

Accession Number

DB01232  (APRD00623)

Type

Small Molecule

Groups

Approved, Investigational

Description

An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem]

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for DB01232 (Saquinavir)

×

Close

Synonyms

• Saquinavir Mesylate
• SQV

External IDs

RO 31-8959/000 / RO-31-8959/000 / SCH-52852

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Fortovase Roche	Capsule	200 mg	Oral	Hoffmann La Roche	1998-11-26	2007-03-06
Invirase	Capsule	200 mg/1	Oral	Remedy Repack	2013-05-01	2016-10-13
Invirase	Capsule	200 mg/1	Oral	Genentech, Inc.	1995-12-06	Not applicable
Invirase	Capsule	200 mg	Oral	Roche Registration Gmb H	1996-10-04	Not applicable
Invirase	Tablet, film coated	500 mg/1	Oral	Genentech, Inc.	2004-12-17	Not applicable
Invirase	Tablet, film coated	500 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Invirase	Tablet, film coated	500 mg	Oral	Roche Registration Gmb H	1996-10-04	Not applicable
Invirase	Tablet	500 mg	Oral	Hoffmann La Roche	2006-04-10	Not applicable
Invirase - Cap 200mg	Capsule	200 mg	Oral	Hoffmann La Roche	1996-12-31	Not applicable

International/Other Brands

Fortovase / ROC

Categories

• Anti-HIV Agents
• Anti-Infective Agents
• Anti-Retroviral Agents
• Antiinfectives for Systemic Use
• Antiviral Agents
• Antivirals for Systemic Use
• BCRP/ABCG2 Inhibitors
• BSEP/ABCB11 Substrates
• Chemically-Induced Disorders
• Combined Inhibitors of CYP3A4 and P-glycoprotein (Strong)
• CYP3A Substrates (Sensitive)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A Inhibitors (strong)
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (strong)
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 CYP3A7 Substrates
• Cytochrome P-450 Enzyme Inhibitors
• Direct Acting Antivirals
• Enzyme Inhibitors
• HIV Protease Inhibitors
• Hyperglycemia-Associated Agents
• Isoquinolines
• Moderate Risk QTc-Prolonging Agents
• OATP1B1/SLCO1B1 Inhibitors
• P-glycoprotein/ABCB1 Inducers
• P-glycoprotein/ABCB1 Inhibitors
• P-glycoprotein/ABCB1 Substrates
• Protease Inhibitors
• QTc Prolonging Agents
• Quinolines

UNII

L3JE09KZ2F

CAS number

127779-20-8

Weight

Average: 670.8408
Monoisotopic: 670.38426874

Chemical Formula

C₃₈H₅₀N₆O₅

InChI Key

QWAXKHKRTORLEM-UGJKXSETSA-N

InChI

InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1

IUPAC Name

(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butyl-C-hydroxycarbonimidoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediimidic acid

SMILES

[H][C@@](O)(CN1C[C@@]2([H])CCCC[C@@]2([H])C[C@@]1([H])C(O)=NC(C)(C)C)[C@]([H])(CC1=CC=CC=C1)N=C(O)[C@]([H])(CC(O)=N)NC(=O)C1=NC2=CC=CC=C2C=C1

Pharmacology

Indication

For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.

Associated Conditions

• Infection, Human Immunodeficiency Virus I

Pharmacodynamics

Saquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Mechanism of action

Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Target	Actions	Organism
AHuman immunodeficiency virus type 1 protease	inhibitor	Human immunodeficiency virus 1

Absorption

Absolute bioavailability averages 4%

Volume of distribution

• 700 L

Protein binding

98%

Metabolism

Hepatic

• Saquinavir
  M2 di-hydroxylated metabolite
• Saquinavir
  (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide
• Saquinavir
  (2S)-N-[(2S,3R)-4-[(3S,4aR,8aS)-3-(tert-butylcarbamoyl)-6-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide
• Saquinavir
  (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-7-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide

Route of elimination

In vitro studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90% of the hepatic metabolism. Only 1% of saquinavir is excreted in the urine, so the impact of renal impairment on saquinavir elimination should be minimal.

Half life

Not Available

Clearance

• 1.14 L/h/kg [Healthy volunteers receiving IV doses of 6, 36, and 72 mg]

Toxicity

Probably experience pain in the throat

Affected organisms

• Human Immunodeficiency Virus

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE	The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Saquinavir.	Experimental
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Saquinavir.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir.	Experimental, Illicit
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Saquinavir.	Investigational
5-androstenedione	The serum concentration of 5-androstenedione can be increased when it is combined with Saquinavir.	Experimental, Illicit
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Saquinavir.	Approved, Investigational
Abemaciclib	The risk or severity of adverse effects can be increased when Saquinavir is combined with Abemaciclib.	Approved, Investigational
Abiraterone	The serum concentration of Saquinavir can be increased when it is combined with Abiraterone.	Approved
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Saquinavir.	Approved, Investigational
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Saquinavir.	Approved, Investigational
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Saquinavir.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Saquinavir.	Approved, Investigational, Withdrawn
Acetyl sulfisoxazole	The metabolism of Saquinavir can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Saquinavir.	Approved
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Saquinavir.	Approved
Agmatine	The metabolism of Agmatine can be decreased when combined with Saquinavir.	Experimental, Investigational
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Saquinavir.	Experimental, Investigational
Albendazole	The metabolism of Albendazole can be decreased when combined with Saquinavir.	Approved, Vet Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Saquinavir.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Saquinavir.	Experimental, Investigational
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Saquinavir.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Saquinavir.	Approved, Investigational
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Saquinavir.	Approved, Investigational
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Saquinavir.	Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Saquinavir.	Approved
Almotriptan	The serum concentration of Almotriptan can be increased when it is combined with Saquinavir.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Saquinavir.	Approved
Alosetron	The serum concentration of Alosetron can be increased when it is combined with Saquinavir.	Approved, Withdrawn
alpha-Tocopherol acetate	The metabolism of alpha-Tocopherol acetate can be decreased when combined with Saquinavir.	Approved
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Saquinavir.	Approved, Illicit, Investigational
Amantadine	Amantadine may increase the QTc-prolonging activities of Saquinavir.	Approved
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Saquinavir.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Saquinavir.	Approved, Investigational
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Saquinavir.	Experimental, Investigational
Amcinonide	The serum concentration of Amcinonide can be increased when it is combined with Saquinavir.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Saquinavir.	Illicit, Withdrawn
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Saquinavir.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Saquinavir.	Approved
Amiodarone	The risk or severity of QTc prolongation, torsade de pointes, and Cardiac Arrhythmia can be increased when Saquinavir is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Saquinavir.	Approved
Amitriptylinoxide	The serum concentration of Amitriptylinoxide can be increased when it is combined with Saquinavir.	Approved, Investigational
Amlodipine	The metabolism of Amlodipine can be decreased when combined with Saquinavir.	Approved
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Saquinavir.	Approved, Investigational
Amoxapine	The serum concentration of Amoxapine can be increased when it is combined with Saquinavir.	Approved
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Saquinavir.	Approved, Investigational
Anagrelide	Saquinavir may increase the QTc-prolonging activities of Anagrelide.	Approved
Androstenedione	The serum concentration of Androstenedione can be increased when it is combined with Saquinavir.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be increased when it is combined with Saquinavir.	Investigational
anecortave acetate	The serum concentration of anecortave acetate can be increased when it is combined with Saquinavir.	Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Saquinavir.	Approved, Investigational
Apalutamide	The serum concentration of Apalutamide can be increased when it is combined with Saquinavir.	Approved, Investigational
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Saquinavir.	Approved
Apomorphine	Apomorphine may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Apremilast	The metabolism of Apremilast can be decreased when combined with Saquinavir.	Approved, Investigational
Aprepitant	The serum concentration of Saquinavir can be increased when it is combined with Aprepitant.	Approved, Investigational
Aranidipine	The metabolism of Aranidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Arformoterol	Arformoterol may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Argatroban	The metabolism of Argatroban can be decreased when combined with Saquinavir.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.	Approved, Investigational
Arsenic trioxide	Saquinavir may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Saquinavir may increase the QTc-prolonging activities of Artemether.	Approved
Asenapine	The serum concentration of Saquinavir can be increased when it is combined with Asenapine.	Approved
Astemizole	The serum concentration of Astemizole can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Asunaprevir	The serum concentration of Asunaprevir can be increased when it is combined with Saquinavir.	Approved, Investigational, Withdrawn
Atamestane	The serum concentration of Atamestane can be increased when it is combined with Saquinavir.	Investigational
Atazanavir	The metabolism of Saquinavir can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	The metabolism of Saquinavir can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Saquinavir is combined with Atorvastatin.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Saquinavir.	Approved
Avatrombopag	The metabolism of Avatrombopag can be decreased when combined with Saquinavir.	Approved, Investigational
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Saquinavir.	Approved
Azelnidipine	The metabolism of Azelnidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Azithromycin	The metabolism of Azithromycin can be decreased when combined with Saquinavir.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Saquinavir.	Investigational
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Saquinavir.	Investigational
Baricitinib	The metabolism of Baricitinib can be decreased when combined with Saquinavir.	Approved, Investigational
Barnidipine	The serum concentration of Barnidipine can be increased when it is combined with Saquinavir.	Approved
Beclomethasone dipropionate	The metabolism of Beclomethasone dipropionate can be decreased when combined with Saquinavir.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be increased when it is combined with Saquinavir.	Approved
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Saquinavir.	Investigational
Bencyclane	The metabolism of Bencyclane can be decreased when combined with Saquinavir.	Experimental
Benidipine	The metabolism of Benidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Saquinavir.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Saquinavir.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Saquinavir.	Approved
Bepridil	Bepridil may increase the arrhythmogenic activities of Saquinavir.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Betaxolol	The metabolism of Saquinavir can be decreased when combined with Betaxolol.	Approved, Investigational
Bexarotene	The metabolism of Bexarotene can be decreased when combined with Saquinavir.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Saquinavir.	Approved, Investigational
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Saquinavir.	Approved
Bictegravir	The metabolism of Bictegravir can be decreased when combined with Saquinavir.	Approved, Investigational
Bioallethrin	The metabolism of Bioallethrin can be decreased when combined with Saquinavir.	Approved, Experimental
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Saquinavir.	Approved
Blonanserin	The metabolism of Blonanserin can be decreased when combined with Saquinavir.	Approved, Investigational
Boceprevir	The serum concentration of Saquinavir can be decreased when it is combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Saquinavir.	Approved, Investigational
Bosentan	The serum concentration of Saquinavir can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Saquinavir.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.	Approved, Investigational
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Saquinavir.	Approved, Investigational
Brigatinib	The serum concentration of Brigatinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Brinzolamide	The serum concentration of Brinzolamide can be increased when it is combined with Saquinavir.	Approved
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Saquinavir.	Approved, Investigational
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Saquinavir.	Approved, Investigational
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Saquinavir.	Approved
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Saquinavir.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Saquinavir.	Investigational, Withdrawn
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Saquinavir.	Approved, Investigational
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Saquinavir.	Approved
Buserelin	Buserelin may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Buspirone	The metabolism of Buspirone can be decreased when combined with Saquinavir.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Saquinavir.	Approved, Investigational
Butriptyline	The serum concentration of Butriptyline can be increased when it is combined with Saquinavir.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Saquinavir.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Saquinavir.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Caffeine	The metabolism of Caffeine can be decreased when combined with Saquinavir.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Saquinavir.	Approved, Nutraceutical
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Saquinavir.	Approved
Cannabidiol	The metabolism of Cannabidiol can be decreased when combined with Saquinavir.	Approved, Investigational
Carbamazepine	The serum concentration of Carbamazepine can be increased when it is combined with Saquinavir.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Saquinavir.	Approved
Carboxyamidotriazole	The metabolism of Carboxyamidotriazole can be decreased when combined with Saquinavir.	Investigational
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Saquinavir.	Experimental
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Saquinavir.	Approved, Investigational
Caroverine	The metabolism of Caroverine can be decreased when combined with Saquinavir.	Experimental
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Saquinavir.	Approved, Investigational
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Saquinavir.	Experimental
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Saquinavir.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Saquinavir.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Saquinavir.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Saquinavir.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Saquinavir.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Saquinavir.	Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational
Chlormadinone	The serum concentration of Chlormadinone can be decreased when it is combined with Saquinavir.	Experimental
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Chlorphenamine	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Chlorphenamine.	Approved
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Saquinavir.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Saquinavir.	Approved, Nutraceutical
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Saquinavir.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Saquinavir.	Experimental
Cilnidipine	The metabolism of Cilnidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Saquinavir.	Approved, Investigational
Cimetidine	Cimetidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Investigational
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Saquinavir.	Approved
Cinnarizine	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Cinnarizine.	Approved, Investigational
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Saquinavir.	Approved, Investigational
Cisapride	Saquinavir may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	Saquinavir may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saquinavir.	Approved
Clemastine	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Clemastine.	Approved, Investigational
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Saquinavir.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Saquinavir.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be increased when it is combined with Saquinavir.	Approved, Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be increased when it is combined with Saquinavir.	Approved
Clobetasone	The serum concentration of Clobetasone can be increased when it is combined with Saquinavir.	Approved
Clocortolone	The serum concentration of Clocortolone can be increased when it is combined with Saquinavir.	Approved
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Saquinavir.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Saquinavir.	Approved, Investigational
clomethiazole	The metabolism of clomethiazole can be decreased when combined with Saquinavir.	Investigational
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Saquinavir.	Approved, Illicit
Clonidine	The metabolism of Clonidine can be decreased when combined with Saquinavir.	Approved
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Saquinavir.	Approved
Clorazepate	The serum concentration of Clorazepate can be increased when it is combined with Saquinavir.	Approved, Illicit
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Saquinavir.	Approved, Illicit
Clotrimazole	The metabolism of Saquinavir can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Clozapine can be decreased when combined with Saquinavir.	Approved
Cobicistat	The serum concentration of Saquinavir can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Cocaine	The metabolism of Cocaine can be decreased when combined with Saquinavir.	Approved, Illicit
Codeine	The metabolism of Codeine can be decreased when combined with Saquinavir.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Saquinavir.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Saquinavir.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Saquinavir.	Approved
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Saquinavir.	Approved, Investigational
Cortexolone 17α-propionate	The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Saquinavir.	Investigational
Corticosterone	The serum concentration of Corticosterone can be increased when it is combined with Saquinavir.	Experimental
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Saquinavir.	Approved, Investigational
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Saquinavir.	Approved
Curcumin	The metabolism of Saquinavir can be decreased when combined with Curcumin.	Approved, Investigational
Cyclandelate	The metabolism of Cyclandelate can be decreased when combined with Saquinavir.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Saquinavir is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Cyproterone acetate	The serum concentration of Cyproterone acetate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Saquinavir.	Approved, Investigational
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir.	Approved
Dabrafenib	The serum concentration of Saquinavir can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Daclatasvir	The serum concentration of Daclatasvir can be increased when it is combined with Saquinavir.	Approved, Investigational
Dantrolene	The metabolism of Dantrolene can be decreased when combined with Saquinavir.	Approved, Investigational
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Saquinavir.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Saquinavir.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Saquinavir.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Saquinavir.	Approved, Investigational
Darodipine	The metabolism of Darodipine can be decreased when combined with Saquinavir.	Experimental
Darunavir	The serum concentration of Darunavir can be decreased when it is combined with Saquinavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Saquinavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Saquinavir.	Approved
Deferasirox	The serum concentration of Saquinavir can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The metabolism of Deflazacort can be decreased when combined with Saquinavir.	Approved, Investigational
Degarelix	Degarelix may increase the QTc-prolonging activities of Saquinavir.	Approved
Delamanid	Saquinavir may increase the QTc-prolonging activities of Delamanid.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Saquinavir.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Saquinavir.	Investigational
Desflurane	Desflurane may increase the QTc-prolonging activities of Saquinavir.	Approved
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Saquinavir.	Approved, Investigational
Desogestrel	The serum concentration of Desogestrel can be decreased when it is combined with Saquinavir.	Approved
Desonide	The serum concentration of Desonide can be increased when it is combined with Saquinavir.	Approved, Investigational
Desoximetasone	The serum concentration of Desoximetasone can be increased when it is combined with Saquinavir.	Approved
Desoxycorticosterone acetate	The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Saquinavir.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Saquinavir.	Experimental, Vet Approved
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.	Approved, Investigational
Deutetrabenazine	The metabolism of Deutetrabenazine can be decreased when combined with Saquinavir.	Approved, Investigational
Dexamethasone	The metabolism of Dexamethasone can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Saquinavir.	Vet Approved
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Saquinavir.	Approved
Dexchlorpheniramine maleate	The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Saquinavir.	Approved
Dexlansoprazole	The serum concentration of Saquinavir can be increased when it is combined with Dexlansoprazole.	Approved, Investigational
Dexniguldipine	The metabolism of Dexniguldipine can be decreased when combined with Saquinavir.	Experimental
Dexrabeprazole	The serum concentration of Saquinavir can be increased when it is combined with Dexrabeprazole.	Experimental
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Saquinavir.	Approved
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational, Withdrawn
Dexverapamil	The metabolism of Dexverapamil can be decreased when combined with Saquinavir.	Experimental
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Saquinavir.	Approved, Illicit, Investigational, Vet Approved
Dibenzepin	The serum concentration of Dibenzepin can be increased when it is combined with Saquinavir.	Experimental
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Saquinavir.	Approved, Vet Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Saquinavir.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Saquinavir.	Approved, Investigational
Diflorasone	The serum concentration of Diflorasone can be increased when it is combined with Saquinavir.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be increased when it is combined with Saquinavir.	Approved, Investigational, Withdrawn
Difluprednate	The serum concentration of Difluprednate can be increased when it is combined with Saquinavir.	Approved
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Saquinavir.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Saquinavir.	Approved
Dihydro-alpha-ergocryptine	The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Saquinavir.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Saquinavir.	Approved, Illicit
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Saquinavir.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Saquinavir.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Saquinavir.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Saquinavir.	Approved, Investigational
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Saquinavir.	Approved, Investigational
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Dimenhydrinate.	Approved
Dimetacrine	The serum concentration of Dimetacrine can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Saquinavir.	Approved, Investigational
Disopyramide	Saquinavir may increase the QTc-prolonging activities of Disopyramide.	Approved
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Saquinavir.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Saquinavir.	Approved, Investigational
Dofetilide	Saquinavir may increase the arrhythmogenic activities of Dofetilide.	Approved, Investigational
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Saquinavir.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Saquinavir.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Saquinavir.	Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Saquinavir.	Approved
Dosulepin	The metabolism of Saquinavir can be decreased when combined with Dosulepin.	Approved
Dotarizine	The metabolism of Dotarizine can be decreased when combined with Saquinavir.	Investigational
Doxazosin	The serum concentration of Saquinavir can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Saquinavir can be increased when it is combined with Doxepin.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Saquinavir.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Saquinavir.	Approved, Investigational
Doxycycline	The metabolism of Saquinavir can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Saquinavir.	Approved, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Saquinavir.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be increased when it is combined with Saquinavir.	Approved
Droperidol	Droperidol may increase the QTc-prolonging activities of Saquinavir.	Approved, Vet Approved
Drospirenone	The serum concentration of Drospirenone can be decreased when it is combined with Saquinavir.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Duloxetine	The metabolism of Saquinavir can be decreased when combined with Duloxetine.	Approved
Dutasteride	The serum concentration of Dutasteride can be increased when it is combined with Saquinavir.	Approved, Investigational
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Saquinavir.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Saquinavir.	Approved
Efavirenz	The risk or severity of adverse effects can be increased when Saquinavir is combined with Efavirenz.	Approved, Investigational
Efonidipine	The metabolism of Efonidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Elbasvir	The metabolism of Elbasvir can be decreased when combined with Saquinavir.	Approved
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Saquinavir.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Saquinavir.	Approved
Eluxadoline	The serum concentration of Eluxadoline can be increased when it is combined with Saquinavir.	Approved, Investigational
Elvitegravir	The metabolism of Elvitegravir can be decreased when combined with Saquinavir.	Approved
Emopamil	The metabolism of Emopamil can be decreased when combined with Saquinavir.	Experimental
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.	Approved
Enalapril	The metabolism of Enalapril can be decreased when combined with Saquinavir.	Approved, Vet Approved
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Saquinavir.	Approved, Investigational
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Saquinavir.	Approved, Investigational
Englitazone	The therapeutic efficacy of Englitazone can be decreased when used in combination with Saquinavir.	Experimental
Enzalutamide	The serum concentration of Saquinavir can be decreased when it is combined with Enzalutamide.	Approved
Eperisone	The metabolism of Eperisone can be decreased when combined with Saquinavir.	Approved, Investigational
Epinastine	The serum concentration of Saquinavir can be increased when it is combined with Epinastine.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Saquinavir.	Approved
Equilenin	The serum concentration of Equilenin can be increased when it is combined with Saquinavir.	Experimental
Equilin	The serum concentration of Equilin can be increased when it is combined with Saquinavir.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Saquinavir.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Saquinavir.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Saquinavir.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Saquinavir.	Approved
Eribulin	Eribulin may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Erythromycin	The metabolism of Erythromycin can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Escitalopram	Saquinavir may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Esomeprazole	The serum concentration of Saquinavir can be increased when it is combined with Esomeprazole.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be increased when it is combined with Saquinavir.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Saquinavir.	Approved, Investigational
Estrogens, esterified	The metabolism of Estrogens, esterified can be decreased when combined with Saquinavir.	Approved
Estrone	The metabolism of Estrone can be decreased when combined with Saquinavir.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Saquinavir.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Saquinavir.	Approved, Investigational
Ethanol	The metabolism of Ethanol can be decreased when combined with Saquinavir.	Approved
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Saquinavir.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Saquinavir.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Saquinavir.	Approved, Illicit
Ethynodiol diacetate	The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Saquinavir.	Approved
Etizolam	The serum concentration of Etizolam can be increased when it is combined with Saquinavir.	Approved
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Saquinavir.	Approved, Investigational
Etoposide	The metabolism of Etoposide can be decreased when combined with Saquinavir.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Saquinavir.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Saquinavir.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Saquinavir.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Saquinavir.	Approved, Investigational
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Ezogabine	Ezogabine may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Saquinavir.	Approved, Investigational
Famotidine	Famotidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved
Felbamate	The metabolism of Felbamate can be decreased when combined with Saquinavir.	Approved
Felodipine	The metabolism of Felodipine can be decreased when combined with Saquinavir.	Approved, Investigational
Fendiline	The metabolism of Fendiline can be decreased when combined with Saquinavir.	Withdrawn
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Saquinavir.	Approved
Fenofibric acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Saquinavir is combined with Fenofibric acid.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Saquinavir.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Saquinavir.	Approved
Fingolimod	The metabolism of Fingolimod can be decreased when combined with Saquinavir.	Approved, Investigational
Fish oil	The metabolism of Fish oil can be decreased when combined with Saquinavir.	Approved, Nutraceutical
Flecainide	Saquinavir may increase the arrhythmogenic activities of Flecainide.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Saquinavir.	Approved, Investigational
Fluasterone	The serum concentration of Fluasterone can be increased when it is combined with Saquinavir.	Investigational
Fluconazole	The metabolism of Saquinavir can be decreased when combined with Fluconazole.	Approved, Investigational
Fludrocortisone	The serum concentration of Fludrocortisone can be increased when it is combined with Saquinavir.	Approved, Investigational
Flumethasone	The serum concentration of Flumethasone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Saquinavir.	Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Saquinavir.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Saquinavir.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Saquinavir.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be increased when it is combined with Saquinavir.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Saquinavir.	Approved, Investigational
Fluoxetine	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	Saquinavir may increase the QTc-prolonging activities of Flupentixol.	Approved, Investigational, Withdrawn
Fluprednidene	The serum concentration of Fluprednidene can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Fluprednisolone	The serum concentration of Fluprednisolone can be increased when it is combined with Saquinavir.	Approved
Flurandrenolide	The serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.	Approved
Flurazepam	The serum concentration of Flurazepam can be increased when it is combined with Saquinavir.	Approved, Illicit, Investigational
Fluspirilene	The metabolism of Fluspirilene can be decreased when combined with Saquinavir.	Approved, Investigational
Flutamide	The metabolism of Flutamide can be decreased when combined with Saquinavir.	Approved, Investigational
Fluticasone	The serum concentration of Fluticasone can be increased when it is combined with Saquinavir.	Approved, Experimental, Investigational
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Saquinavir.	Approved
Fluticasone propionate	The serum concentration of Fluticasone propionate can be increased when it is combined with Saquinavir.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Saquinavir.	Approved
Fluvoxamine	The serum concentration of Saquinavir can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formestane	The serum concentration of Formestane can be increased when it is combined with Saquinavir.	Approved, Investigational, Withdrawn
Formoterol	Formoterol may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Fosamprenavir	The metabolism of Fosamprenavir can be decreased when combined with Saquinavir.	Approved
Fosaprepitant	The serum concentration of Saquinavir can be increased when it is combined with Fosaprepitant.	Approved
Foscarnet	Foscarnet may increase the QTc-prolonging activities of Saquinavir.	Approved
Fosnetupitant	The metabolism of Fosnetupitant can be decreased when combined with Saquinavir.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Saquinavir.	Approved, Investigational
Fostamatinib	The metabolism of Fostamatinib can be decreased when combined with Saquinavir.	Approved, Investigational
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Saquinavir.	Approved, Investigational
Fusidic Acid	The serum concentration of Fusidic Acid can be increased when it is combined with Saquinavir.	Approved, Investigational
Gabapentin	The metabolism of Gabapentin can be decreased when combined with Saquinavir.	Approved, Investigational
Gadobenic acid	Gadobenic acid may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Galantamine	The metabolism of Galantamine can be decreased when combined with Saquinavir.	Approved
Gallopamil	The metabolism of Gallopamil can be decreased when combined with Saquinavir.	Investigational
Garlic	The serum concentration of Saquinavir can be decreased when it is combined with Garlic.	Approved, Nutraceutical
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Saquinavir.	Approved, Investigational
Gemfibrozil	The metabolism of Gemfibrozil can be decreased when combined with Saquinavir.	Approved
Gemifloxacin	Gemifloxacin may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Gestodene	The serum concentration of Gestodene can be decreased when it is combined with Saquinavir.	Approved, Investigational
Gestrinone	The serum concentration of Gestrinone can be decreased when it is combined with Saquinavir.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Saquinavir.	Investigational, Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Saquinavir.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Saquinavir.	Approved
Glipizide	The metabolism of Glipizide can be decreased when combined with Saquinavir.	Approved, Investigational
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Saquinavir.	Approved, Investigational
Glyburide	The metabolism of Glyburide can be decreased when combined with Saquinavir.	Approved
Glycerin	The serum concentration of Saquinavir can be increased when it is combined with Glycerin.	Approved, Investigational
Goserelin	Goserelin may increase the QTc-prolonging activities of Saquinavir.	Approved
Granisetron	The metabolism of Granisetron can be decreased when combined with Saquinavir.	Approved, Investigational
Grazoprevir	The metabolism of Grazoprevir can be decreased when combined with Saquinavir.	Approved
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Guanfacine	The serum concentration of Guanfacine can be increased when it is combined with Saquinavir.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Saquinavir.	Investigational
Halcinonide	The serum concentration of Halcinonide can be increased when it is combined with Saquinavir.	Approved, Investigational, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Saquinavir.	Approved
Haloperidol	The metabolism of Haloperidol can be decreased when combined with Saquinavir.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Saquinavir.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be increased when it is combined with Saquinavir.	Investigational
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Saquinavir.	Approved
Histamine	The metabolism of Histamine can be decreased when combined with Saquinavir.	Approved, Investigational
Histrelin	Histrelin may increase the QTc-prolonging activities of Saquinavir.	Approved
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Saquinavir.	Approved, Illicit
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Saquinavir.	Approved, Vet Approved
Hydrocortisone acetate	The metabolism of Hydrocortisone acetate can be decreased when combined with Saquinavir.	Approved, Vet Approved
Hydrocortisone butyrate	The metabolism of Hydrocortisone butyrate can be decreased when combined with Saquinavir.	Approved, Vet Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Saquinavir.	Approved, Illicit
Hydroxyprogesterone caproate	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Saquinavir.	Approved
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Saquinavir.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Saquinavir.	Approved
Ibuprofen	The serum concentration of Saquinavir can be increased when it is combined with Ibuprofen.	Approved
Ibutilide	Saquinavir may increase the QTc-prolonging activities of Ibutilide.	Approved
Icotinib	The metabolism of Icotinib can be decreased when combined with Saquinavir.	Approved, Investigational
Idelalisib	The serum concentration of Saquinavir can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Saquinavir resulting in a loss in efficacy.	Approved
Iloperidone	The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Saquinavir.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Saquinavir.	Approved
Imidafenacin	The serum concentration of Imidafenacin can be increased when it is combined with Saquinavir.	Approved, Investigational
Imipramine	The metabolism of Imipramine can be decreased when combined with Saquinavir.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Saquinavir.	Approved, Investigational
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Saquinavir.	Approved
Indapamide	The metabolism of Indapamide can be decreased when combined with Saquinavir.	Approved
Indinavir	The metabolism of Saquinavir can be decreased when combined with Indinavir.	Approved
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Saquinavir.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Saquinavir.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Saquinavir.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Saquinavir.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Saquinavir.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Saquinavir.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Saquinavir.	Approved
Ipecac	The metabolism of Ipecac can be decreased when combined with Saquinavir.	Approved, Withdrawn
Ipratropium	The metabolism of Ipratropium can be decreased when combined with Saquinavir.	Approved
Iprindole	The serum concentration of Iprindole can be increased when it is combined with Saquinavir.	Experimental
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Saquinavir.	Approved, Investigational
Isavuconazole	The serum concentration of Isavuconazole can be increased when it is combined with Saquinavir.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Saquinavir.	Approved, Investigational
Isoflurane	Isoflurane may increase the QTc-prolonging activities of Saquinavir.	Approved, Vet Approved
Isoniazid	The metabolism of Saquinavir can be decreased when combined with Isoniazid.	Approved, Investigational
Isosorbide Dinitrate	The metabolism of Isosorbide Dinitrate can be decreased when combined with Saquinavir.	Approved, Investigational
Isosorbide Mononitrate	The metabolism of Isosorbide Mononitrate can be decreased when combined with Saquinavir.	Approved
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Saquinavir.	Approved, Investigational
Istaroxime	The serum concentration of Istaroxime can be increased when it is combined with Saquinavir.	Investigational
Itraconazole	The serum concentration of Saquinavir can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Saquinavir.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Saquinavir.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be increased when it is combined with Saquinavir.	Approved, Investigational
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Saquinavir.	Approved, Investigational
Ketamine	The metabolism of Ketamine can be decreased when combined with Saquinavir.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Saquinavir.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Saquinavir.	Approved, Investigational
Ketoconazole	The serum concentration of Ketoconazole can be increased when it is combined with Saquinavir.	Approved, Investigational
Lacidipine	The serum concentration of Lacidipine can be increased when it is combined with Saquinavir.	Approved, Investigational
Lacosamide	The serum concentration of Lacosamide can be increased when it is combined with Saquinavir.	Approved
Lafutidine	The serum concentration of Saquinavir can be increased when it is combined with Lafutidine.	Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Saquinavir.	Approved, Investigational
Lamotrigine	The metabolism of Lamotrigine can be decreased when combined with Saquinavir.	Approved, Investigational
Lansoprazole	The serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Saquinavir.	Investigational
Lavoltidine	The serum concentration of Saquinavir can be increased when it is combined with Lavoltidine.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Saquinavir.	Approved
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Saquinavir.	Approved
Lenvatinib	The metabolism of Lenvatinib can be decreased when combined with Saquinavir.	Approved, Investigational
Lercanidipine	The serum concentration of Lercanidipine can be increased when it is combined with Saquinavir.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Saquinavir.	Approved, Investigational
Leuprolide	Leuprolide may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Levetiracetam	The metabolism of Levetiracetam can be decreased when combined with Saquinavir.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be increased when it is combined with Saquinavir.	Approved, Investigational
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Saquinavir.	Approved
Levofloxacin	Levofloxacin may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Saquinavir.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Saquinavir.	Approved, Investigational
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Saquinavir.	Approved, Investigational
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Saquinavir.	Approved
Lidocaine	Saquinavir may increase the arrhythmogenic activities of Lidocaine.	Approved, Vet Approved
Lidoflazine	The metabolism of Lidoflazine can be decreased when combined with Saquinavir.	Experimental
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Saquinavir.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Saquinavir.	Approved
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Saquinavir.	Approved, Investigational
Lithium cation	Lithium may increase the QTc-prolonging activities of Saquinavir.	Experimental
Lofepramine	The serum concentration of Lofepramine can be increased when it is combined with Saquinavir.	Experimental
Lomerizine	The metabolism of Lomerizine can be decreased when combined with Saquinavir.	Experimental
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Saquinavir.	Approved, Investigational
Loperamide	The metabolism of Loperamide can be decreased when combined with Saquinavir.	Approved
Lopinavir	Saquinavir may increase the QTc-prolonging activities of Lopinavir.	Approved
Loratadine	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Loratadine.	Approved, Investigational
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Saquinavir.	Approved
Lorpiprazole	The serum concentration of Saquinavir can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Saquinavir.	Approved
Loteprednol	The serum concentration of Loteprednol can be increased when it is combined with Saquinavir.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Saquinavir.	Approved, Investigational
Luliconazole	The serum concentration of Saquinavir can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Saquinavir can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The serum concentration of Lumefantrine can be increased when it is combined with Saquinavir.	Approved
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Saquinavir.	Approved, Investigational
Lynestrenol	The serum concentration of Lynestrenol can be decreased when it is combined with Saquinavir.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Saquinavir.	Illicit, Investigational, Withdrawn
Macimorelin	The metabolism of Macimorelin can be decreased when combined with Saquinavir.	Approved, Investigational
Macitentan	The serum concentration of Macitentan can be increased when it is combined with Saquinavir.	Approved
Magnesium sulfate	The metabolism of Magnesium sulfate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Manidipine	The metabolism of Manidipine can be decreased when combined with Saquinavir.	Approved, Investigational
Maprotiline	Maprotiline may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Maraviroc	The serum concentration of Maraviroc can be increased when it is combined with Saquinavir.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be increased when it is combined with Saquinavir.	Investigational
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Saquinavir.	Approved, Vet Approved
Medical Cannabis	The metabolism of Medical Cannabis can be decreased when combined with Saquinavir.	Experimental, Investigational
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be increased when it is combined with Saquinavir.	Approved
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Saquinavir.	Approved, Investigational
Megestrol acetate	The serum concentration of Megestrol acetate can be decreased when it is combined with Saquinavir.	Approved, Investigational, Vet Approved
Melengestrol	The serum concentration of Melengestrol can be increased when it is combined with Saquinavir.	Vet Approved
Melitracen	The serum concentration of Melitracen can be increased when it is combined with Saquinavir.	Experimental, Investigational
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Saquinavir.	Approved, Vet Approved
Menthol	The metabolism of Menthol can be decreased when combined with Saquinavir.	Approved
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Saquinavir.	Approved, Vet Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Saquinavir.	Approved
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Saquinavir.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.	Approved
Methadone	Methadone may increase the QTc-prolonging activities of Saquinavir.	Approved
Methantheline	The serum concentration of Saquinavir can be increased when it is combined with Methantheline.	Approved, Investigational
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Saquinavir.	Illicit, Withdrawn
Methotrimeprazine	The metabolism of Saquinavir can be decreased when combined with Methotrimeprazine.	Approved, Investigational
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Saquinavir.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Saquinavir.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Saquinavir.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Saquinavir.	Approved
Metiamide	The serum concentration of Saquinavir can be increased when it is combined with Metiamide.	Experimental
Metoclopramide	The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Saquinavir.	Approved, Investigational
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Saquinavir.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Saquinavir.	Experimental
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Saquinavir.	Approved, Investigational
Mianserin	The metabolism of Mianserin can be decreased when combined with Saquinavir.	Approved, Investigational
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Saquinavir.	Investigational, Withdrawn
Miconazole	The metabolism of Miconazole can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Saquinavir.	Approved, Illicit
Midecamycin	The metabolism of Midecamycin can be decreased when combined with Saquinavir.	Approved
Midostaurin	The metabolism of Midostaurin can be decreased when combined with Saquinavir.	Approved, Investigational
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Mifepristone	The serum concentration of Saquinavir can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Saquinavir.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Saquinavir.	Approved
Mirabegron	The metabolism of Mirabegron can be decreased when combined with Saquinavir.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Saquinavir.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Mitotane	The serum concentration of Saquinavir can be decreased when it is combined with Mitotane.	Approved
Modafinil	The metabolism of Modafinil can be decreased when combined with Saquinavir.	Approved, Investigational
Moexipril	Moexipril may increase the QTc-prolonging activities of Saquinavir.	Approved
Mometasone	The serum concentration of Mometasone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Saquinavir.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Saquinavir.	Approved, Investigational
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Saquinavir.	Approved, Investigational
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Saquinavir.	Approved, Investigational
Nabiximols	The metabolism of Nabiximols can be decreased when combined with Saquinavir.	Approved, Investigational
Naftopidil	The metabolism of Naftopidil can be decreased when combined with Saquinavir.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Saquinavir.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Saquinavir.	Approved, Vet Approved
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Saquinavir.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be increased when it is combined with Saquinavir.	Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Nelfinavir	The metabolism of Saquinavir can be decreased when combined with Nelfinavir.	Approved
Neratinib	The metabolism of Neratinib can be decreased when combined with Saquinavir.	Approved, Investigational
Netupitant	The serum concentration of Saquinavir can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The serum concentration of Saquinavir can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Saquinavir.	Approved, Investigational
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Saquinavir.	Approved, Investigational
Nicotine	The metabolism of Nicotine can be decreased when combined with Saquinavir.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Saquinavir.	Approved
Niguldipine	The metabolism of Niguldipine can be decreased when combined with Saquinavir.	Experimental
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Niludipine	The metabolism of Niludipine can be decreased when combined with Saquinavir.	Experimental
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Saquinavir.	Approved, Investigational
Nimesulide	The metabolism of Nimesulide can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Saquinavir.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Saquinavir.	Approved
Niperotidine	The serum concentration of Saquinavir can be increased when it is combined with Niperotidine.	Experimental, Investigational
Nisoldipine	The serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Saquinavir.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Saquinavir.	Approved, Investigational
Nizatidine	The serum concentration of Saquinavir can be increased when it is combined with Nizatidine.	Approved
Nomegestrol acetate	The serum concentration of Nomegestrol acetate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Norelgestromin	The serum concentration of Norelgestromin can be decreased when it is combined with Saquinavir.	Approved, Investigational
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Saquinavir.	Approved
Norethynodrel	The serum concentration of Norethynodrel can be decreased when it is combined with Saquinavir.	Approved
Norfloxacin	Norfloxacin may increase the QTc-prolonging activities of Saquinavir.	Approved
Norgestimate	The serum concentration of Norgestimate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Saquinavir.	Approved
Norgestrienone	The serum concentration of Norgestrienone can be decreased when it is combined with Saquinavir.	Experimental
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Saquinavir.	Approved
Nylidrin	The metabolism of Nylidrin can be decreased when combined with Saquinavir.	Approved
Octreotide	Octreotide may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Odanacatib	The metabolism of Odanacatib can be decreased when combined with Saquinavir.	Investigational
Ofloxacin	Ofloxacin may increase the QTc-prolonging activities of Saquinavir.	Approved
Olanzapine	The serum concentration of Saquinavir can be increased when it is combined with Olanzapine.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Saquinavir.	Approved
Oleoyl-estrone	The serum concentration of Oleoyl-estrone can be increased when it is combined with Saquinavir.	Investigational
Olodaterol	Olodaterol may increase the QTc-prolonging activities of Saquinavir.	Approved
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Saquinavir.	Approved
Omeprazole	The serum concentration of Saquinavir can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Saquinavir.	Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Saquinavir.	Investigational
Opium	The metabolism of Opium can be decreased when combined with Saquinavir.	Approved, Illicit
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Saquinavir.	Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Saquinavir.	Approved
Ospemifene	The serum concentration of Ospemifene can be increased when it is combined with Saquinavir.	Approved, Investigational
Otilonium	The metabolism of Otilonium can be decreased when combined with Saquinavir.	Experimental, Investigational
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Saquinavir.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be increased when it is combined with Saquinavir.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Saquinavir is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Oxytocin	Oxytocin may increase the QTc-prolonging activities of Saquinavir.	Approved, Vet Approved
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Saquinavir.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be increased when it is combined with Saquinavir.	Approved, Investigational
Paliperidone	Saquinavir may increase the QTc-prolonging activities of Paliperidone.	Approved
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Saquinavir.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Saquinavir.	Approved, Investigational
Pantoprazole	The serum concentration of Saquinavir can be increased when it is combined with Pantoprazole.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Saquinavir.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Saquinavir.	Approved
Parecoxib	The serum concentration of Parecoxib can be increased when it is combined with Saquinavir.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Saquinavir.	Approved, Investigational
Paroxetine	The risk or severity of QTc prolongation can be increased when Paroxetine is combined with Saquinavir.	Approved, Investigational
Pasireotide	Pasireotide may increase the QTc-prolonging activities of Saquinavir.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Saquinavir.	Approved
Peginterferon alfa-2b	The serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Penfluridol	The metabolism of Penfluridol can be decreased when combined with Saquinavir.	Experimental
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Saquinavir.	Approved, Investigational
Pentobarbital	The serum concentration of Pentobarbital can be increased when it is combined with Saquinavir.	Approved, Investigational, Vet Approved
Perampanel	The metabolism of Perampanel can be decreased when combined with Saquinavir.	Approved
Perflutren	Perflutren may increase the QTc-prolonging activities of Saquinavir.	Approved
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Saquinavir.	Approved, Investigational, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Saquinavir.	Approved, Investigational
Permethrin	The metabolism of Permethrin can be decreased when combined with Saquinavir.	Approved, Investigational
Perospirone	The metabolism of Perospirone can be decreased when combined with Saquinavir.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Saquinavir.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Saquinavir is combined with Pethidine.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Saquinavir.	Withdrawn
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Saquinavir.	Approved, Investigational, Withdrawn
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Saquinavir.	Approved
Phenobarbital	The serum concentration of Phenobarbital can be increased when it is combined with Saquinavir.	Approved, Investigational
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Saquinavir.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Saquinavir.	Approved, Investigational
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Saquinavir.	Approved, Investigational
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Saquinavir.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Saquinavir.	Approved
Pinacidil	The metabolism of Pinacidil can be decreased when combined with Saquinavir.	Approved
Pinaverium	The metabolism of Pinaverium can be decreased when combined with Saquinavir.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Saquinavir.	Approved, Investigational
Piperaquine	The metabolism of Piperaquine can be decreased when combined with Saquinavir.	Approved, Investigational
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Saquinavir.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Saquinavir.	Approved
Pitolisant	The serum concentration of Pitolisant can be increased when it is combined with Saquinavir.	Approved, Investigational
Podofilox	The metabolism of Podofilox can be decreased when combined with Saquinavir.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Saquinavir.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Posaconazole	The metabolism of Posaconazole can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Pranlukast	The serum concentration of Pranlukast can be increased when it is combined with Saquinavir.	Approved, Investigational
Prasterone	The metabolism of Prasterone can be decreased when combined with Saquinavir.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The serum concentration of Prasterone sulfate can be increased when it is combined with Saquinavir.	Investigational
Prasugrel	The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Saquinavir resulting in a loss in efficacy.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Saquinavir.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Prednicarbate	The serum concentration of Prednicarbate can be increased when it is combined with Saquinavir.	Approved, Investigational
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Pregabalin	The metabolism of Pregabalin can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational
Pregnenolone	The serum concentration of Pregnenolone can be increased when it is combined with Saquinavir.	Approved, Experimental, Investigational
Prenylamine	The metabolism of Prenylamine can be decreased when combined with Saquinavir.	Withdrawn
Primaquine	The metabolism of Primaquine can be decreased when combined with Saquinavir.	Approved
Primidone	The serum concentration of Primidone can be increased when it is combined with Saquinavir.	Approved, Vet Approved
Procainamide	Saquinavir may increase the QTc-prolonging activities of Procainamide.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Saquinavir.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Saquinavir.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Saquinavir.	Approved
Promazine	The metabolism of Promazine can be decreased when combined with Saquinavir.	Approved, Vet Approved
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Saquinavir.	Approved, Investigational
Propafenone	Saquinavir may increase the arrhythmogenic activities of Propafenone.	Approved
Propiverine	The metabolism of Propiverine can be decreased when combined with Saquinavir.	Approved, Investigational
Propofol	The metabolism of Propofol can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Saquinavir.	Approved, Investigational
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Saquinavir.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Saquinavir.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Saquinavir.	Approved, Investigational
Quazepam	The metabolism of Quazepam can be decreased when combined with Saquinavir.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be increased when it is combined with Saquinavir.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Saquinavir.	Approved, Investigational
Quingestanol	The serum concentration of Quingestanol can be decreased when it is combined with Saquinavir.	Experimental
Quinidine	Saquinavir may increase the QTc-prolonging activities of Quinidine.	Approved, Investigational
Quinine	Saquinavir may increase the QTc-prolonging activities of Quinine.	Approved
Rabeprazole	The serum concentration of Saquinavir can be increased when it is combined with Rabeprazole.	Approved, Investigational
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Saquinavir.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be increased when it is combined with Saquinavir.	Approved, Investigational
Ranitidine	Ranitidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Saquinavir.	Approved, Investigational
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Saquinavir.	Approved, Investigational
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Saquinavir.	Approved
Repaglinide	The serum concentration of Repaglinide can be increased when it is combined with Saquinavir.	Approved, Investigational
Retapamulin	The serum concentration of Retapamulin can be increased when it is combined with Saquinavir.	Approved
Ribociclib	The serum concentration of Ribociclib can be increased when it is combined with Saquinavir.	Approved, Investigational
Rifabutin	The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Saquinavir.	Approved, Investigational
Rifampicin	The serum concentration of Saquinavir can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Rifapentine can be increased when it is combined with Saquinavir.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Saquinavir.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Saquinavir.	Approved
Rimexolone	The serum concentration of Rimexolone can be increased when it is combined with Saquinavir.	Approved
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Saquinavir.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Saquinavir.	Approved
Risperidone	The metabolism of Risperidone can be decreased when combined with Saquinavir.	Approved, Investigational
Ritonavir	The metabolism of Ritonavir can be decreased when combined with Saquinavir.	Approved, Investigational
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Saquinavir.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Saquinavir.	Approved, Investigational
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Saquinavir.	Approved, Investigational
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Saquinavir.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Saquinavir.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Saquinavir.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Saquinavir.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Saquinavir.	Approved
Roxatidine acetate	The serum concentration of Saquinavir can be increased when it is combined with Roxatidine acetate.	Approved, Investigational
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Rucaparib	The metabolism of Rucaparib can be decreased when combined with Saquinavir.	Approved, Investigational
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Saquinavir.	Approved
Ruxolitinib	The serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir.	Approved
Safinamide	The metabolism of Safinamide can be decreased when combined with Saquinavir.	Approved, Investigational
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Saquinavir.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Saquinavir.	Approved
Sarilumab	The therapeutic efficacy of Saquinavir can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Saquinavir.	Approved
Selegiline	The metabolism of Selegiline can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Seletracetam	The metabolism of Seletracetam can be decreased when combined with Saquinavir.	Investigational
Selexipag	The metabolism of Selexipag can be decreased when combined with Saquinavir.	Approved
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Saquinavir.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Sertraline	The metabolism of Sertraline can be decreased when combined with Saquinavir.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Saquinavir.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Saquinavir.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Saquinavir.	Approved
Siltuximab	The serum concentration of Saquinavir can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Saquinavir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Saquinavir.	Approved
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Saquinavir.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Saquinavir.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Saquinavir.	Approved
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Saquinavir.	Approved
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Saquinavir.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Saquinavir.	Approved, Investigational
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Saquinavir.	Investigational
Sotalol	Saquinavir may increase the QTc-prolonging activities of Sotalol.	Approved
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Saquinavir.	Approved
St. John's Wort	The metabolism of Saquinavir can be increased when combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Saquinavir can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Saquinavir.	Approved, Investigational
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Saquinavir.	Approved
Sulfasalazine	The serum concentration of Sulfasalazine can be increased when it is combined with Saquinavir.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Saquinavir.	Approved
Sulfisoxazole	Sulfisoxazole may increase the QTc-prolonging activities of Saquinavir.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Sumatriptan	The serum concentration of Sumatriptan can be increased when it is combined with Saquinavir.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Saquinavir.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be increased when it is combined with Saquinavir.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Saquinavir.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Saquinavir.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Saquinavir.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be increased when it is combined with Saquinavir.	Approved, Investigational
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Saquinavir.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be increased when it is combined with Saquinavir.	Approved, Investigational
Tasimelteon	The serum concentration of Tasimelteon can be increased when it is combined with Saquinavir.	Approved, Investigational
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Saquinavir.	Approved
Taurochenodeoxycholic acid	The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Saquinavir.	Experimental
Telaprevir	The metabolism of Telaprevir can be decreased when combined with Saquinavir.	Approved, Withdrawn
Telavancin	Saquinavir may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The metabolism of Saquinavir can be decreased when combined with Telithromycin.	Approved
Temazepam	The metabolism of Temazepam can be decreased when combined with Saquinavir.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Saquinavir is combined with Temsirolimus.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Saquinavir.	Approved
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Terbutaline	Terbutaline may increase the QTc-prolonging activities of Saquinavir.	Approved
Terfenadine	The serum concentration of Terfenadine can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Saquinavir.	Experimental
Terodiline	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Terodiline.	Experimental
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Saquinavir.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Saquinavir.	Approved, Investigational
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Saquinavir.	Approved
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Saquinavir.	Approved
Testosterone propionate	The metabolism of Testosterone propionate can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The metabolism of Testosterone undecanoate can be decreased when combined with Saquinavir.	Approved, Investigational
Tetrabenazine	Saquinavir may increase the QTc-prolonging activities of Tetrabenazine.	Approved, Investigational
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Saquinavir.	Approved, Vet Approved
Tetrahydropalmatine	The metabolism of Tetrahydropalmatine can be decreased when combined with Saquinavir.	Investigational
Tetrandrine	The metabolism of Tetrandrine can be decreased when combined with Saquinavir.	Experimental
Tezacaftor	The metabolism of Tezacaftor can be decreased when combined with Saquinavir.	Approved, Investigational
Theophylline	The metabolism of Theophylline can be decreased when combined with Saquinavir.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Saquinavir.	Approved, Investigational
Thiothixene	Thiothixene may increase the QTc-prolonging activities of Saquinavir.	Approved
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Saquinavir.	Approved, Investigational
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Saquinavir.	Approved, Investigational
Ticagrelor	The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Saquinavir resulting in a loss in efficacy.	Approved
Ticlopidine	The metabolism of Ticlopidine can be decreased when combined with Saquinavir.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Saquinavir.	Approved, Investigational
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Saquinavir.	Approved
Tipranavir	The serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be increased when it is combined with Saquinavir.	Approved, Withdrawn
Tizanidine	Tizanidine may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Tocilizumab	The serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.	Approved
Tocofersolan	The metabolism of Tocofersolan can be decreased when combined with Saquinavir.	Approved
Tocopherol	The metabolism of Tocopherol can be decreased when combined with Saquinavir.	Approved, Investigational
Tofacitinib	The serum concentration of Tofacitinib can be increased when it is combined with Saquinavir.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Saquinavir.	Approved, Investigational
Tolfenamic Acid	The metabolism of Tolfenamic Acid can be decreased when combined with Saquinavir.	Approved, Investigational
Tolterodine	The serum concentration of Tolterodine can be increased when it is combined with Saquinavir.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Saquinavir.	Approved
Topiramate	The serum concentration of Topiramate can be increased when it is combined with Saquinavir.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Saquinavir.	Approved, Investigational
Toremifene	The risk or severity of adverse effects can be increased when Saquinavir is combined with Toremifene.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Saquinavir.	Approved, Investigational
Tramadol	The serum concentration of Tramadol can be increased when it is combined with Saquinavir.	Approved, Investigational
Tranilast	The metabolism of Tranilast can be decreased when combined with Saquinavir.	Approved, Investigational
Tranylcypromine	The metabolism of Saquinavir can be decreased when combined with Tranylcypromine.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Saquinavir.	Approved, Investigational
Trazodone	Saquinavir may increase the QTc-prolonging activities of Trazodone.	Approved, Investigational
Treprostinil	Treprostinil may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Saquinavir.	Approved, Investigational, Nutraceutical
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Saquinavir.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Saquinavir.	Approved, Investigational
Trimebutine	The metabolism of Trimebutine can be decreased when combined with Saquinavir.	Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Saquinavir.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Saquinavir.	Approved, Vet Approved
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Saquinavir.	Approved
Triptorelin	Triptorelin may increase the QTc-prolonging activities of Saquinavir.	Approved, Vet Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Saquinavir.	Investigational, Withdrawn
Troleandomycin	The metabolism of Troleandomycin can be decreased when combined with Saquinavir.	Approved
Udenafil	The metabolism of Udenafil can be decreased when combined with Saquinavir.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Saquinavir.	Approved
Ulobetasol	The serum concentration of Ulobetasol can be increased when it is combined with Saquinavir.	Approved
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Saquinavir.	Approved, Investigational
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Valproic Acid	The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Valproic Acid.	Approved, Investigational
Vandetanib	Saquinavir may increase the QTc-prolonging activities of Vandetanib.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Saquinavir.	Investigational
Vardenafil	The serum concentration of Vardenafil can be increased when it is combined with Saquinavir.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Saquinavir.	Approved
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Saquinavir.	Approved, Investigational
Vemurafenib	The serum concentration of Vemurafenib can be increased when it is combined with Saquinavir.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Saquinavir.	Approved, Investigational
Venlafaxine	The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Saquinavir.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Saquinavir.	Approved
Vicriviroc	The metabolism of Vicriviroc can be decreased when combined with Saquinavir.	Investigational
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Saquinavir.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Saquinavir.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Saquinavir.	Approved, Investigational
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Saquinavir.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Saquinavir.	Approved, Investigational
Vincristine	The metabolism of Vincristine can be decreased when combined with Saquinavir.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Saquinavir.	Approved, Investigational
Vinflunine	The metabolism of Vinflunine can be decreased when combined with Saquinavir.	Approved, Investigational
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Saquinavir.	Approved, Investigational
Vinpocetine	The metabolism of Vinpocetine can be decreased when combined with Saquinavir.	Investigational
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Saquinavir.	Approved, Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Saquinavir.	Approved, Investigational
Vorapaxar	The serum concentration of Vorapaxar can be increased when it is combined with Saquinavir.	Approved
Voriconazole	The metabolism of Saquinavir can be decreased when combined with Voriconazole.	Approved, Investigational
Vorinostat	Vorinostat may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Saquinavir.	Approved, Investigational
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Saquinavir.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Saquinavir.	Approved
WIN 55212-2	The metabolism of WIN 55212-2 can be decreased when combined with Saquinavir.	Experimental
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Saquinavir.	Approved, Investigational, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Saquinavir.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Saquinavir.	Approved, Investigational
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Saquinavir.	Approved, Illicit, Investigational
Ziconotide	The metabolism of Ziconotide can be decreased when combined with Saquinavir.	Approved
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Saquinavir.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Ziprasidone	Saquinavir may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Saquinavir.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Saquinavir.	Withdrawn
Zonisamide	The metabolism of Zonisamide can be decreased when combined with Saquinavir.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Saquinavir.	Approved
Zotepine	The metabolism of Zotepine can be decreased when combined with Saquinavir.	Approved, Investigational, Withdrawn
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Saquinavir.	Approved, Investigational

Food Interactions

• Take after a full meal.

References

Synthesis Reference

US5196438

General References

1. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L: Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001 Jul;185(1):178-81. [PubMed:11483925]

External Links

KEGG Drug

D00429

PubChem Compound

441243

PubChem Substance

46508726

ChemSpider

390016

BindingDB

519

ChEBI

63621

ChEMBL

CHEMBL114

Therapeutic Targets Database

DAP000171

PharmGKB

PA451305

HET

ROC

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Saquinavir

ATC Codes

J05AE01 — Saquinavir

• J05AE — Protease inhibitors
• J05A — DIRECT ACTING ANTIVIRALS
• J05 — ANTIVIRALS FOR SYSTEMIC USE
• J — ANTIINFECTIVES FOR SYSTEMIC USE

AHFS Codes

• 08:18.08.08 — HIV Protease Inhibitors

PDB Entries

1c6z / 1fb7 / 1hxb / 2nmy / 2nmz / 2nnk / 2nnp / 3cyx / 3d1x / 3d1y …

show 17 more

FDA label

Download (362 KB)

MSDS

Download (15.8 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Unknown Status	Treatment	Pulmonary Arterial Hypertension (PAH)	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	10
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
1, 2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	3
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	22
2	Completed	Treatment	IDV Associated Nephrotoxicity	1
2	Completed	Treatment	Sarcomas	1
2	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2	Withdrawn	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2, 3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	3
3	Completed	Not Available	Directly Observed Therapy / Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Treatment	AIDS-Associated Nephropathy / Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	10
4	Completed	Diagnostic	Cardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome	1
4	Completed	Prevention	Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Treatment	Healthy Volunteers / Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	5
Not Available	Completed	Prevention	Ischemia, Cerebral	1
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	4

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• A-S Medication Solutions LLC
• F Hoffmann La Roche Ltd.
• F Hoffmann-La Roche Ltd.
• Pharmaceutical Utilization Management Program VA Inc.
• Physicians Total Care Inc.
• R.P. Scherer GmbH and Co. KG

Dosage forms

Form	Route	Strength
Capsule	Oral	200 mg/1
Tablet	Oral	500 mg
Tablet, film coated	Oral	500 mg/1
Tablet, film coated	Oral	500 mg
Capsule	Oral	200 mg

Prices

Unit description	Cost	Unit
Invirase 500 mg tablet	8.72USD	tablet
Invirase 200 mg capsule	3.87USD	capsule
Fortovase 200 mg capsule	1.46USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5196438	No	1993-11-19	2010-11-19
CA2224125	No	2004-09-28	2016-06-04
CA2030433	No	1997-10-21	2010-11-21
US6352717	Yes	2000-05-16	2020-05-16
US6008228	Yes	1995-12-06	2015-12-06

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	349.84 °C	Not Available
water solubility	Insoluble	Not Available
logP	3.8	Not Available
Caco2 permeability	-6.26	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.00765 mg/mL	ALOGPS
logP	3.96	ALOGPS
logP	2.58	ChemAxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	5.11	ChemAxon
pKa (Strongest Basic)	8.31	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	10	ChemAxon
Hydrogen Donor Count	6	ChemAxon
Polar Surface Area	174.72 Å2	ChemAxon
Rotatable Bond Count	13	ChemAxon
Refractivity	198.65 m3·mol-1	ChemAxon
Polarizability	74.25 Å3	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.7774
Blood Brain Barrier	-	0.9949
Caco-2 permeable	-	0.8957
P-glycoprotein substrate	Substrate	0.9048
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Inhibitor	0.5195
Renal organic cation transporter	Non-inhibitor	0.8612
CYP450 2C9 substrate	Non-substrate	0.8593
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Substrate	0.7406
CYP450 1A2 substrate	Non-inhibitor	0.8729
CYP450 2C9 inhibitor	Non-inhibitor	0.7442
CYP450 2D6 inhibitor	Non-inhibitor	0.8536
CYP450 2C19 inhibitor	Non-inhibitor	0.7124
CYP450 3A4 inhibitor	Inhibitor	0.5219
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9053
Ames test	Non AMES toxic	0.8489
Carcinogenicity	Non-carcinogens	0.865
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.6007 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9687
hERG inhibition (predictor II)	Inhibitor	0.8153

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Quinolines and derivatives

Sub Class

Quinoline carboxamides

Direct Parent

Quinoline carboxamides

Alternative Parents

Phenylbutylamines / Amphetamines and derivatives / Pyridinecarboxylic acids and derivatives / Piperidinecarboxamides / 2-heteroaryl carboxamides / Aralkylamines / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Secondary alcohols1,2-aminoalcohols / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Azacyclic compounds / Hydrocarbon derivatives / Organopnictogen compounds / Organic oxides

show 8 more

Substituents

Quinoline-2-carboxamide / Phenylbutylamine / Amphetamine or derivatives / 2-piperidinecarboxamide / Piperidinecarboxamide / Pyridine carboxylic acid or derivatives / 2-heteroaryl carboxamide / Aralkylamine / Monocyclic benzene moiety / PiperidinePyridine / Benzenoid / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / Secondary carboxylic acid amide / Secondary alcohol / Amino acid or derivatives / 1,2-aminoalcohol / Carboxamide group / Azacycle / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid derivative / Amine / Organonitrogen compound / Organooxygen compound / Organic oxygen compound / Organopnictogen compound / Organic nitrogen compound / Organic oxide / Alcohol / Hydrocarbon derivative / Aromatic heteropolycyclic compound

show 26 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

quinolines, L-asparagine derivative (CHEBI:63621)

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:50